The Prevalence of the Aortic to Radial Pressure Gradient in States of Shock, Outside the Context of Cardiac Surgery, a Prospective Study

ConditionShock
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorHospices Civils de Lyon

About this trial

First described in cardiac surgery, the aortic to radial pressure gradient (ATRAP) is the cause of an underestimation of the aortic pressure with a measure assumed with a radial catheter, and he can concert 1 of 3rd patients. The risks factor well known are small height, previous hypertension, long and difficult surgery, radial artery diameter less than 1.8mm.

The ATRAP definition is a pressure difference between radial and femoral (same of the aortic pressure) pressure of 25mmHg on the systolic pressure, or a pressure difference on the mean pressure of 10mmHg, both measures realised by arterial canulation, and with a duration superior than 5 minutes.

If this gradient appears in pathophysiological specifics situations, there is a risk of inappropriate administration of vasopressors, with more hospitalisation days, more side effect of vasopressors like an augmentation of myocardial work.

The ATRAP is documented in septic shock with a prevalence between 21% and 27%. The ATRAP can appear in shocks, moreover with doses of equivalent norepinephrine of 0.5 µg/kg/min who is use for the definition of refractive shock, the difference between the two pressure is higher if the dose of equivalent norepinephrine is higher than 1µg/kg/min. But the prevalence and risks factors are barely unknowns in this situation.

Most of the time, a radial arterial catheter is used for hemodynamic monitoring for his simplicity of utilisation and the lows complications associated. Some medical teams in cardiac surgeries, or in intensive care unit (ICU) for the management of shocks used often radial and femoral arterial catheter. It seems there is no at risk for the utilisation of a radial and femoral arterial canulation.

Out of the situation of cardiac surgery, there is a lack of information of the ATRAP, the objective of the study is to evaluate the prevalence of the ATRAP in shock, out of the situation of cardiac surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

age superior or equal 18 years

Vasopressors support superior or equal 0.5 µg/kg/min of equivalent norepinephrine

Invasive monitoring of blood pressure with a radial arterial catheter and a femoral arterial catheter decided by de physician

Beginning of the shock less than 48 hours.

Disqualifiers

perioperative of cardiac surgery (between the beginning of the surgery and 7 days after)

pregnant woman or breast-feeding

Major person under protection

Person with privation of liberty by a justice decision, or an administrative decision

Trial population

180 patients of intensive care unit (ICU), in shock with equal or more than 0.5µg/kg/min of norepinephrine equivalent, who are not in perioperative of cardiac surgery. And who have a monitoring of arterial pressure by a radial catheter, and for who the physician decided to put in place a femoral arterial catheter.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Non-invasive blood pressure measurements

    Other intervention

    Non-invasive blood pressure measurements to the tension cuff three times in a row on each side (right arm and left arm)

Treatment groups

180 Participants
are divided into 1 treatment group
Group A: Intensive care unit patient with shock, who don't be in perioperative of cardiac surgery1 intervention

Trial outcomes

Primary outcomes

1

Prevalence (percentage) of ATRAP is determined by the ratio of patients with ATRAP to total. ATRAP is defined by a 25mmHg systolic or 10mmHg mean pressure difference between radial and femoral arterial pressures during more than 5 minutes.

The prevalence of the ATRAP will be show in percentage (%), with his confidence interval at 95%.

Time frame
The primary outcome will be measure at the inclusion of the patient when the femoral arterial catheter will be in place.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.